KM Research Hub
← 返回论文库
待处理 入排:符合 图源:待检查 入排置信度 0.96

Final prespecified analysis of the phase III LITESPARK-011 study: belzutifan plus lenvatinib versus cabozantinib for advanced renal cell carcinoma after anti-PD-(L)1 therapy.

D Y C Heng, M Schmidinger, R McDermott, S H Park, M Burotto, C Ciccarese, E Verzoni, C Suárez, M Eto, H J Cutuli, C Porta, R Manneh Kopp, S Rottey, G de Velasco, B P Valderrama, A A Azad, U De Giorgi, M Pavic, P Tomczak, R Figlin, H M Westgeest, A Guida, A Necchi, F A Schutz, B B M Suelmann, J B A G Haanen, J Lin, R F Perini, D Vickery, R J Motzer, LITESPARK-011 Investigators

Ann Oncol S0923-7534(26)06893-6

PMID42927855
PMCID-
DOI10.1016/j.annonc.2026.10.109
发表日期2026-10-25
入排依据:明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
摘要

摘要

BACKGROUND: The phase III, randomized, open-label LITESPARK-011 trial (NCT04586231) investigated belzutifan plus lenvatinib versus cabozantinib in participants with advanced clear-cell renal cell carcinoma (ccRCC) following anti-programmed death-ligand 1 or anti-programmed death-1 [anti-PD-(L)1] therapy. At earlier analyses, belzutifan plus lenvatinib significantly improved progression-free survival (PFS) and objective response rate (ORR) versus cabozantinib. Overall survival (OS) was tested but did not reach significance. We present the final analysis of LITESPARK-011. PARTICIPANTS AND METHODS: Adult participants with advanced ccRCC that progressed on or after anti-PD-(L)1 therapy were randomly assigned (1 : 1) to 120 mg belzutifan plus 20 mg lenvatinib or 60 mg cabozantinib orally once daily until disease progression or unacceptable adverse events. Dual primary endpoints were PFS by blinded independent central review (BICR) and OS. ORR by BICR was a key secondary endpoint; safety and duration of response (DOR) by BICR were secondary endpoints. RESULTS: At final analysis, median time from randomization to data cut-off date (2 February 2026) was 38.8 months (range, 29.1-59.0). A total of 371 participants were assigned to belzutifan plus lenvatinib and 376 to cabozantinib. Belzutifan plus lenvatinib continued to demonstrate benefit versus cabozantinib in PFS [hazard ratio (HR) 0.74, 95% confidence interval (CI) 0.62-0.88], ORR (53.1% versus 40.2%), and DOR (22.0 versus 11.9 months). Mature OS results did not reach statistical significance at final analysis [median 33.7 versus 28.6 months; HR 0.85, 95% CI 0.70-1.03; one-sided P = 0.04689 (prespecified boundary 0.0223)]. Grade ≥3 treatment-emergent adverse events occurred in 85.4% of the belzutifan plus lenvatinib group versus 83.0% of the cabozantinib group. CONCLUSIONS: Belzutifan plus lenvatinib continued to demonstrate PFS, ORR, and DOR benefit versus cabozantinib with additional follow-up; OS favored the combination but did not reach statistical significance at final analysis. Safety profile of belzutifan plus lenvatinib remained consistent with each drug as monotherapy. These findings continue to support belzutifan plus lenvatinib as a treatment option in advanced ccRCC following anti-PD-(L)1 therapy.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。